ST. LOUIS, MO – September 21, 2015 – Veran Medical Technologies Inc., a privately-held medical device company and leader in image-guided endobronchial and percutaneous technology for diagnosis of lung cancer and therapy delivery, has completed a $30.6 million financing, led by Versant Ventures and River Cities Capital Funds. The financing was oversubscribed with participation from existing investors Prolog Ventures, Advantage Capital, Rex Health Ventures, 3G Capital, Dynamic Investments, and Vectis. The financing will support Veran’s commercial expansion in the U.S. and entry into international markets.

View full version here

(Visited 72 times, 1 visits today)